""

Bristol-Myers Squibb Company recently released its 2025 Q4 earnings call presentation, providing an overview of the company's financial performance. The pharmaceutical giant reported its fourth-quarter results, highlighting key achievements and progress in its pipeline. As of the end of 2025, Bristol-Myers Squibb has demonstrated significant growth, driven by its oncology and immunology franchises. The company's revenue and earnings per share exceeded analyst expectations, with total revenues reaching approximately $12.2 billion. Bristol-Myers Squibb's CEO, Giovanni Caforio, attributed the strong performance to the company's focus on innovation and its commitment to delivering life-changing medicines to patients. The company's Q4 results reflect its ongoing efforts to expand its portfolio and strengthen its position in the global pharmaceutical market. With a strong finish to 2025, Bristol-Myers Squibb is well-positioned for continued growth and success in the coming year, driven by its robust pipeline and strategic investments.